← BioAge Labs, Inc. (BIOA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioAge Labs, Inc. (BIOA)
Pharmaceutical Preparations · market cap $369M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
BioAge Labs (BIOA) is a ~$1.0B market-cap clinical-stage pharmaceutical company whose entire pipeline consists of a single oral asset, BGE-102, currently in Phase 2 for obesity and cardiovascular risk reduction. The company carries $241.8M in cash (~30 months of runway) against an $81M net loss in 2025, with no product revenue. The key binary event is estimated Phase 2 data readout by November 2026.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2026-11-30 (est.)Phase 2 · Oral BGE-102imp 7/10
- 2026-12-31Data Readoutimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Oral BGE-102 | Phase 2 | Obesity and Cardiovascular Risk |
| Anti-VEGF | Phase 2 | Diabetic Macular Edema (DME) |
Price & technical context
3-month
-73.1%
6-month
-61.8%
12-month
+12.8%
52-wk range
$5.11–$25.10
vs 50-day MA
-36.7%
vs 200-day MA
-60.0%
Realized vol
132.1%
Max drawdown
-88.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BIOA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.